ページの先頭です
HOME > Past Issue List > Issue List > Abstract
言語を選択(Language)
日本語(Japanese)English

Abstract

Vol.74 No.6 November 2026

Disproportionality analysis of hypokalemia associated with tazobactam/piperacillin using the Japanese Adverse Drug Event Report database: evaluation of time-to-onset and patient demographics

Taku Ueda1), Yui Ogawa1) and Kiyotaka Imai1)

1)Department of Pharmacy, Toyooka Public Hospital, 1094 Tobera, Toyooka, Hyogo, Japan

Abstract

Although hypokalemia induced by the penicillin-class antimicrobial agent tazobactam/piperacillin (TAZ/PIPC) is recognized as a severe adverse event, comprehensive evaluations using large-scale data remain limited. This study evaluated the association between TAZ/PIPC treatment and the risk of hypokalemia, the time-to-onset, and differences in reporting disproportionality based on the patient demographics using a spontaneous reporting database. A disproportionality analysis was conducted using data in the Japanese Adverse Drug Event Report database recorded from April 2004 to May 2025. The reporting odds ratio was calculated and compared with the values for benzylpenicillin, ampicillin, sulbactam/ampicillin, piperacillin, fosfomycin, meropenem, cefepime, and tazobactam/ceftolozane. Furthermore, the time-to-onset of hypokalemia was analyzed, and the degree of reporting disproportionality among patient demographic groups was compared using the relative reporting odds ratio (rROR).
Among 1,457,231 reports in the database, 5,470 cases of hypokalemia were identified, with TAZ/PIPC identified as the suspected drug in 43 cases. Among the compared antimicrobial agents, a safety signal was detected exclusively for TAZ/PIPC. The median time-to-onset was four days after initiation of treatment with TAZ/PIPC, with the majority of cases occurring within one week of treatment initiation. In the subgroup comparison using rROR, a significantly pronounced disproportionality was observed in females as compared with males (rROR 2.15, 95% confidence interval: 1.16-4.00). Conversely, no significant differences were confirmed based on older age (≥70 years) or estimated body mass index. TAZ/PIPC-associated hypokalemia tends to occur in the early stages of administration, with a particularly prominent disproportionality demonstrated in females. These findings suggest that this adverse event is likely due to the drug-specific pharmacological mechanisms rather than simple sodium loading or confounding by the treatment indication. Intensive electrolyte monitoring is recommended during the first week of TAZ/PIPC administration.

Key word

tazobactam/piperacillin, hypokalemia, antimicrobial stewardship

Received

March 6, 2026

Accepted

July 27, 2026

Jpn. J. Chemother. 74 (6): 753-761, 2026